This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Hydrochlorothiazide (HCTZ)
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict NOT-RELEVANT HIGH
HCTZ is a first-line antihypertensive — useful for documented hypertension, mild heart failure, kidney stones. a user in this archetype has no hypertension, no heart failure, normal renal function. Bodybuilding "cutting" use carries severe electrolyte risks. Would change only if a user in this archetype develops sustained HTN (unlikely at 20).
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (this-archetype) | NOT-RELEVANT | No HTN. Hyponatremia would crash cognition. WADA-prohibited (S5). |
30-50, executive maintenance | RELEVANT IF HTN | first-line option (or chlorthalidone for longer T1/2). Otherwise NOT-RELEVANT. |
50+, mild cognitive decline | RELEVANT | IF HTN as part of dementia prevention via BP control. Watch hyponatremia risk in elderly — many switch to chlorthalidone or amlodipine. |
Anxiety-prone | NOT-RELEVANT | for nootropic reasons. If HTN exists, cardio-selective beta blocker may be more anxiety-friendly. |
High athletic load, tested status | SKIP | (WADA prohibited as masking agent + diuretic, S5). Tested athletes face automatic bans. |
Sleep-disordered | NOT-RELEVANT | directly, but evening dosing can cause nocturia → fragmented sleep. If used, take AM. |
Recovery-focused | NOT-RELEVANT | — |
Strength/anabolic-focused | SKIP | for cutting use. Documented competition deaths. Even non-tested federations have lost competitors. Use diet/sodium manipulation instead. If competing, do so under medical supervision with K+ monitoring — not a DIY tool. |
- ★20-30, brain-priority, high cognitive workload (this-archetype)NOT-RELEVANT
No HTN. Hyponatremia would crash cognition. WADA-prohibited (S5).
- 30-50, executive maintenanceRELEVANT IF HTN
first-line option (or chlorthalidone for longer T1/2). Otherwise NOT-RELEVANT.
- 50+, mild cognitive declineRELEVANT
IF HTN as part of dementia prevention via BP control. Watch hyponatremia risk in elderly — many switch to chlorthalidone or amlodipine.
- Anxiety-proneNOT-RELEVANT
for nootropic reasons. If HTN exists, cardio-selective beta blocker may be more anxiety-friendly.
- High athletic load, tested statusSKIP
(WADA prohibited as masking agent + diuretic, S5). Tested athletes face automatic bans.
- Sleep-disorderedNOT-RELEVANT
directly, but evening dosing can cause nocturia → fragmented sleep. If used, take AM.
- Recovery-focusedNOT-RELEVANT
- Strength/anabolic-focusedSKIP
for cutting use. Documented competition deaths. Even non-tested federations have lost competitors. Use diet/sodium manipulation instead. If competing, do so under medical supervision with K+ monitoring — not a DIY tool.
▸ Subjective experience (deep)
- Within hours: increased urination, mild thirst, mild lightheadedness on standing
- Days 1-3: continued diuresis, possible muscle cramps if K+/Mg drop
- Chronic use: usually well-tolerated at 12.5-25 mg in HTN management
- High-dose / cutting use (50-100 mg+): pronounced thirst, dizziness, weakness, cramps, palpitations, potential syncope
▸ Tolerance + cycling deep dive
- No pharmacologic tolerance (effective for years in HTN)
- Diuretic effect partially attenuates over weeks (compensated by RAAS), but BP effect persists
▸ Stacking deep dive
Synergistic with
- Medical: ACEi/ARB combos (lisinopril/HCTZ, valsartan/HCTZ, telmisartan/HCTZ) — synergistic BP lowering with K+ neutralization
- Medical: Loop diuretic in resistant edema (sequential nephron blockade)
Avoid stacking with
- Lithium (HCTZ ↑ lithium reabsorption → toxicity)
- Other K+-wasting drugs (loop diuretics, corticosteroids, amphotericin) without supplementation
- Bodybuilding: Other diuretics (furosemide stacked with thiazide for "synergy") — has killed competitors
- Beta-2 agonists (clenbuterol stack — additive K+ loss)
- NSAIDs chronically (blunts BP effect, raises kidney injury risk)
Neutral / safe co-administration
- Most non-cardiac biohacker compounds are neutral if HCTZ is medically indicated
▸ Drug interactions deep dive
- ↑ lithium toxicity (significant)
- ↑ digoxin toxicity (via hypokalemia)
- ↓ effect of antidiabetic drugs (mild hyperglycemia)
- NSAIDs blunt BP-lowering effect
- Cholestyramine reduces absorption
▸ Pharmacogenomics
- SLC12A3 polymorphisms exist but not clinically actionable for HCTZ dosing
- HLA-related cutaneous reaction risk not as well-characterized as for some other drugs
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Generic Rx (US) | Any pharmacy | $4-10/month at 25 mg | high | Standard generic |
| Combo products | Various (with lisinopril, losartan, etc.) | varies | high | Standard antihypertensive |
| Bodybuilding gray-market | Various | varies | low | Black-market diuretic stacks (often combined with K+ supplements that don't fully compensate) |
For the user: Don't source.
▸ Biomarkers to track (deep)
- Baseline (if starting medically): BMP (Na, K, Cl, HCO3, BUN, Cr, glucose), Mg, uric acid, lipid panel
- During use: BMP at 1-2 weeks then quarterly; Mg as needed; annual BMP and lipids
- Post-cycle: N/A — chronic medical use
▸ Controversies / open debates Live debate
- HCTZ vs chlorthalidone: Chlorthalidone has longer half-life (40-60h vs 6-15h), more 24h BP coverage, more outcome data. Many cardiology groups prefer it. HCTZ persists due to formulary inertia and combo-product convenience.
- Skin cancer signal: Pedersen 2018 + Danish series triggered EMA/FDA label updates. Real but in absolute terms small for short-term use; consequential for decades-long chronic exposure.
- Bodybuilding cutting practice persists despite documented deaths (Mohammed Benaziza 1992 widely attributed to diuretic-induced K+/electrolyte collapse; multiple subsequent cases). Practice continues because pre-show "dry" look is competition-rewarded.
▸ Verdict change log
- 2026-05-06 — Initial verdict: NOT-RELEVANT HIGH. Filed alongside novolin-r, BMP-2, OGP as part of the user's "user-dump completeness" wave. No clinical or biohacker use case for him.
▸ Open questions / gaps Open
- Whether SCC risk is materially different for chlorthalidone (similar mechanism, similar photosensitization expected) — emerging.
- Whether SGLT2 inhibitors will displace thiazides in HTN management (not yet, but watch).
References
ALLHAT Officers (2002) — Major outcomes in high-risk hypertensive patients randomized to ACEI vs CCB vs diuretic. JAMA
PMID 12479763, landmark HTN trial
View StudyPedersen SA, et al. (2018) — Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol
PMID 29217346, the SCC signal
View StudyRoush GC, et al. (2012) — Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension
PMID 22232136, head-to-head with chlorthalidone
View StudyAl-Falahi Z, et al. (2022) — Sudden cardiac death in athletes: where are we now? Heart
PMID 35105657, athlete sudden death context (electrolyte/diuretic share)
View StudySica DA (2004) — Diuretic-related side effects: development and treatment. J Clin Hypertens
PMID 15539962, classic safety review
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.